

CITATION REPORT

List of articles citing

Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer

DOI: 10.1634/theoncologist.2018-0773
Oncologist, 2019, 24, e1034-e1043.

Source: <https://exaly.com/paper-pdf/74186869/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
9	Predictors of new-onset heart failure and overall survival in metastatic breast cancer patients treated with liposomal doxorubicin. <i>Scientific Reports</i> , 2020 , 10, 18481	4.9	4
8	Troponins and Natriuretic Peptides in Cardio-Oncology Patients-Data From the ECoR Registry. <i>Frontiers in Pharmacology</i> , 2020 , 11, 740	5.6	1
7	Cardiovascular Outcomes in Relation to Antihypertensive Medication Use in Women with and Without Cancer: Results from the Womens Health Initiative. <i>Oncologist</i> , 2020 , 25, 712-721	5.7	0
6	Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020 , 22, 1504-1524	12.3	74
5	Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021 ,	1.9	0
4	Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer. 2022 , 15,		0
3	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).		4
2	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).		39
1	Cyclin Dependent Kinase 4/6 Inhibitor-Associated Thromboembolism: A Critical Evaluation of the Current Evidence. 2022 ,		0